Pharma Pulse: Antengene–UCB $1.18 Billion License Agreement and AI-Driven Value Chain Efficiencies Podcast Por arte de portada

Pharma Pulse: Antengene–UCB $1.18 Billion License Agreement and AI-Driven Value Chain Efficiencies

Pharma Pulse: Antengene–UCB $1.18 Billion License Agreement and AI-Driven Value Chain Efficiencies

Escúchala gratis

Ver detalles del espectáculo
In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while AI partnerships and Pharma 4.0 technologies accelerate drug development and manufacturing efficiency.
Todavía no hay opiniones